[1] U.S. Food and Drug Administration, What are Generic Drugs?

[2] Ibid.

[3] Das M, Choudhury S, Maity S, Hazra A, Pradhan T, Pal A, Roy RK. Generic versus Branded Medicines: An Observational Study Among Patients with Chronic Diseases Attending a Public Hospital Outpatient Department. J Nat Sci Biol Med. 2017 Jan-Jun;8(1):26-31. doi: 10.4103/0976-9668.198351. PMID: 28250671; PMCID: PMC5320819.

[4] Aswini Priya, "The Role of Generic Medicines in Bridging Healthcare Gaps on a Global Scale," Invimeds (Mar. 01, 2024), https://invimeds.com/updates/the-role-of-generic-medicines-in-bridging-healthcare-gaps-on-a-global-scale/. (last visited Mar. 15, 2024)

[5] Ibid

[6] George, Thomas & Baliga, Shrinath. (2021). Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study. Cureus. 13. e19231. 10.7759/cureus.19231.

[7] Yuxi Tian, Berthold Reichardt, Daniela Dunkler, Milan Hronsky, Wolfgang C. Winkelmayer, Anna Bucsics, Susanne Strohmaier & Georg Heinze, Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study, Sci Rep 10, 5964 (2020).

[8] Ibid.

[9] Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, 'Jan Aushadhi Scheme: Making Medicines Affordable for All,' Indian Journal of Pharmaceutical Sciences (2021), https://janaushadhi.gov.in/article.php?id=1234

[10] Parliamentary Standing Committee on Health and Family Welfare, Forty-Fifth Report on Issues Relating to Availability of Generic, Generic-Branded and Branded Medicines, their Formulation and Therapeutic Efficacy and Effectiveness, Aug. 4, 2010.

[11] U.S. Food and Drug Administration, Understanding Generic Drugs,

https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ (last visited Jan. 15, 2024).

[12] Puskar, Generic Drugs – Why is it Important?, (Oct. 23, 2011) http://greencleanguide.com/generic-drugs/

[13] Viral Shah, Evolution of Pharmaceutical Industry: An Indian Perspective 2 JPSBR: Issue 5, 219, 229 (2012).

[14] Pradeep Agarwal and P. Saibaba, TRIPS and India’s Pharmaceutical Industry, Economic and Political Weekly, Vol.36, No.39 (Sep. 29- Oct. 5, 2001), 3787

[15] Richard A. Spinello, Ethics, Pricing and the Pharmaceutical Industry, The Journal of Law & Economics, Vol.43, No.2 (October 2000), 311.

[16] Ibid.

[17] Ibid.

[18] Sanjaya Lall, Multinational Companies and Concentration: The Case of the Pharmaceutical Industry, Social Scientist, Vol.7, No.8/9, (Mar. – Apr, 1979), pp.3-29.

[19] Ibid.

[20] Viral Shah, Evolution of Pharmaceutical Industry: An Indian Perspective 2 JPSBR: Issue 5, 219, 229 (2012).

[21] Ibid.

[22] National pharmaceutical pricing authority. https://pharmaceuticals.gov.in/national-pharmaceutical-pricing-authority 2013;13 [Google Scholar]

[23] Bhaskarabhatla A, Chatterjee C, Anurag P, Pennings E, Mitigating regulatory impact: the case of partial price controls on metformin in India. Health Policy Plan. 2017;32:194–204

[24] Ahmad A, Khan MU, Patel I., Drug pricing policies in one of the largest drug manufacturing nations in the world: are affordability and access a cause for concern? J Res Pharm Pract. 2015;4:1–3.

[25] Bharuga M., An overview on the National Pharmaceutical Pricing Policy. http://www.iclr.in/assets/pdf/AN%20OVERVIEW%20ON%20THE%20NATIONAL%20PHARMACEUTICAL%20PRICING%20POLICY,%202012.pdf 2012, (last visited 01 Mar, 2024)

[26] Ibid

[27] Ibid

[28] National list of essential medicines of India. https://pharmaceuticals.gov.in/sites/default/files/NLEM.pdf 2011

[29] An overview on the National Pharmaceutical Pricing Policy. Bharuga M. http://www.iclr.in/assets/pdf/AN%20OVERVIEW%20ON%20THE%20NATIONAL%20PHARMACEUTICAL%20PRICING%20POLICY,%202012.pdf, (last visited 01 Mar, 2024)

[30] Guan X, Wushouer H, Yang M, Han S, Shi L, Ross-Degnan D, Wagner AK. Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ Open. 2019;9:0.

[31] Hsu JC, Wei CF, Yang SC, Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. BMJ Open. 2019;9:0.

[32] Bhaskarabhatla A, Chatterjee C, Anurag P, Pennings E. Mitigating regulatory impact: the case of partial price controls on metformin in India. Health Policy Plan. 2017;32:194–204.

[33] Selvaraj S, Farooqui HH, Mehta A. Does price regulation affect atorvastatin sales in India? An impact assessment through interrupted time series analysis. BMJ Open. 2019;9:0.

[34] https://janaushadhi.gov.in/pmjy.aspx (last visited Mar. 11, 2024).

[35] Ibid.

[36] Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, Annual Report 2021-22 available at https://janaushadhi.gov.in/annual_report.aspx  (last visited Mar. 11, 2024)

[37] Ibid.

[38] Sajitha Venkatesan, Most recent cancer drugs offer few benefits, India’s top cancer hospital says, BMJ 2017;357:j2129

[39] https://www.business-standard.com/content/b2b-pharma/govt-plans-to-open-300-amrit-pharmacies-to-dispense-low-cost-drugs-116081600610_1.html (last visited, 15. Mar. 2024)

[40] Parmar A, Pal A, Sharma P. National List of Essential Medicines 2022 of India: Perspectives from Psychiatrists. Indian J Psychol Med. 2023 Jul;45(4):411-414. doi: 10.1177/02537176231155328. Epub 2023 Feb 16. PMID: 37483582; PMCID: PMC10357919.

[41] Marcolino MS, Oliveira JAQ, D'Agostino M, Ribeiro AL, Alkmim MBM, Novillo-Ortiz D. The Impact of mHealth Interventions: Systematic Review of Systematic Reviews. JMIR Mhealth Uhealth. 2018 Jan 17;6(1):e23. doi: 10.2196/mhealth.8873. PMID: 29343463; PMCID: PMC5792697.